The changing landscape of thromboprophylaxis for atrial fibrillation: insights from the ISPAF-2 survey
- 57 Downloads
Atrial fibrillation is the most common sustained cardiac dysrhythmia. It represents a major public health problem due to increased mortality risk, reduced quality of life, and increased health costs [1, 2].
The prevalence of nonvalvular atrial fibrillation (AF) continues to increase worldwide, largely affecting the elderly, but also occurring in younger patients as a result of structural heart disease, autonomic imbalance, genetic abnormality, or previous cardiac surgery . The rise in prevalence of AF is largely due to the increasing age of the population. About 1–2% of the total population is affected by AF, but the prevalence of this condition rises to ≈ 10% in individuals aged > 75 years [1, 2, 3]. In Europe, the number of adults with AF is rising markedly, with 9 million affected individuals in 2010, and 17 million expected patients in 2050, with an alarming impact on morbidity and mortality . The associated fivefold risk of stroke is one of the most feared complications of...
The authors report no specific funding in relation to the preparation of this paper.
Compliance with ethical standards
Conflict of interest
The author(s) declare that they have no conflict of interest.
Statement of human and animal rights
This article does not contain any studies with human participants or animal performed by any of the authors.
No informed consent is required.
- 2.January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: A report of the American college of cardiology/American heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol 64:2245–2280. https://doi.org/10.1016/j.jacc.2014.03.021 CrossRefGoogle Scholar
- 10.Larsen TB, Skjøth F, Nielsen PB et al (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353:i3189. https://doi.org/10.1136/BMJ.I3189 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Volterrani M, Iellamo F, Alberto C et al (2018) NOAC in “real world” patients with atrial fibrillation in Italy: results from the ISPAF-2 (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study. 2 Intern Emerg Med. https://doi.org/10.1007/s11739-018-1896-9 (in press) CrossRefPubMedGoogle Scholar